Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that naltrexone did not significantly reduce hair pulling in adults with trichotillomania compared to placebo, although it improved cognitive flexibility.

This study concluded that ALRV5XR treatment significantly increased terminal hair density in both men and women with androgenetic alopecia and telogen effluvium, with more pronounced effects in women.

This case report describes a 6-year-old girl diagnosed with the rare concurrence of monilethrix and trichorrhexis nodosa, characterized by sparse, brittle hair, who showed minimal clinical improvement with low-dose oral and topical minoxidil treatment.

This study found that 4-(ethoxycarbophenyl) retinamide (RI) exhibited significantly lower acute, subacute, and chronic toxicity compared to other retinoids in mouse and rat models.

In this case report, a 26-year-old man with alopecia universalis, resistant to multiple standard treatments, achieved complete and sustained hair regrowth with ruxolitinib, highlighting its potential as a promising option for patients with refractory AU.

This systematic review identified topical and oral minoxidil as the most effective treatments for monilethrix, but noted the varying efficacy of oral retinoids and other treatments.

This review explores the use of skin penetration enhancers like Transcutol® in various formulation systems, discussing their mechanisms and effectiveness in improving transdermal drug delivery without breaching the skin.

This study found that bupropion SR may improve symptoms in female trichotillomania patients who did not respond to SSRIs, with benefits maintained through a 16-month follow-up.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

This case study describes a 15-year-old girl with a Sertoli–Leydig cell tumor who showed high androgen levels and steroidogenic responses similar to patients with polycystic ovary syndrome before surgery.

This study showed that intralesional injections of pentoxifylline may be an effective and safe alternative to triamcinolone acetonide for treating localized alopecia areata.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This clinical letter identifies Rothmund-Thomson syndrome type 2 as a rare cause of chronic wounds, but provides no new experimental findings.

This study at Gajra Raja Medical College found that topical methotrexate with tretinoin was more effective but not significantly better than betamethasone with tretinoin for treating alopecia areata over six months, with similar safety profiles between the treatments.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.